Biomaarks Drugs India Profile
Key Indicators
- Authorised Capital ₹ 1.15 Cr
as on 10-07-2024
- Paid Up Capital ₹ 9.82 M
as on 10-07-2024
- Company Age 19 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.17 Cr
as on 10-07-2024
- Revenue -14.29%
(FY 2021)
- Profit 99.66%
(FY 2021)
- Ebitda 99.59%
(FY 2021)
- Net Worth -5.34%
(FY 2021)
- Total Assets -5.34%
(FY 2021)
About Biomaarks Drugs India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.15 Cr and a paid-up capital of Rs 9.82 M.
The company has closed loans amounting to ₹2.17 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ketchaani Makesh, Suresh Kumar, Ravichandran Subbiah, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232TN2005PTC057223
- Company No.
057223
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- LocationChennai 600030, Tamil Nadu
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biomaarks Drugs India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Muthusamy Soundaiyan  | Managing Director | 19-Aug-2005 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ketchaani Makesh | Director | 03-Sep-2010 | Current |
| Suresh Kumar | Director | 19-Aug-2005 | Current |
| Ravichandran Subbiah | Director | 19-Aug-2005 | Current |
Financial Performance and Corporate Structure Insights of Biomaarks Drugs India.
Biomaarks Drugs India Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 14.29% decrease. The company also saw a substantial improvement in profitability, with a 99.66% increase in profit. The company's net worth dipped by a decrease of 5.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biomaarks Drugs India?
In 2021, Biomaarks Drugs India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Biomiicron Pharma India Private LimitedActive 12 years 5 monthsKetchaani Makesh and Suresh Kumar are mutual person
Nattura Bio-Care Private LimitedActive 26 years 5 monthsKetchaani Makesh and Suresh Kumar are mutual person
- Tanmed Pharma India Private LimitedActive 9 years 6 months
Ketchaani Makesh and Suresh Kumar are mutual person
- Gray Anon Formulations Private LimitedActive 32 years 5 months
Ravichandran Subbiah is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 12 Jan 2006 | ₹2.17 Cr | Satisfied |
How Many Employees Work at Biomaarks Drugs India?
Unlock and access historical data on people associated with Biomaarks Drugs India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biomaarks Drugs India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biomaarks Drugs India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
